Clinical outcomes and prognostic factors of adult's Ewing sarcoma family of tumors: Single center experience

Creative Commons License

Uyeturk U., Helvaci K., Demirci A., Sonmez O. U., Turker I., Afsar C. U., ...More

Wspolczesna Onkologia, vol.20, no.2, pp.141-146, 2016 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 2
  • Publication Date: 2016
  • Doi Number: 10.5114/wo.2016.58487
  • Journal Name: Wspolczesna Onkologia
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.141-146
  • Keywords: Ewing's sarcoma family of tumors, adult, treatment, PRIMITIVE NEUROECTODERMAL TUMOR, LOCAL-CONTROL, CHEMOTHERAPY, BONE, TEMOZOLOMIDE, IFOSFAMIDE, IRINOTECAN, VINCRISTINE, ETOPOSIDE, DIAGNOSIS
  • Lokman Hekim University Affiliated: No

Abstract

Aim of the study was to investigate the demographics of Ewing sarcoma family of tumours (ESTF) patients, treatment alternatives, clinical outcomes, and prognostic factors for survival. Material and methods: We retrospectively reviewed 39 patients with ESFT who were admitted to our institute between September 2008 and September 2012. Results: The patients included 32 (82.1%) males and seven (17.9%) females of median age 24 (range, 18-66) years. Among the 27 patients with a primary osseous localization, 17 (43.5%) had a central axis localization. Fifteen patients (38.5%) had metastases at the time of diagnosis. Patients were followed up for a median period of 18 (range, 2-134) months. The median eventfree survival (EFS) was 23 (range, 1-64) months, and the 1-and 4-year EFS were 60% and 48%, respectively. The median overall survival (OS) was 91 (range, 1-188) months, and the 1-and 4-year OS were 78% and 54%, respectively. Gender, age, primary tumor site, and local treatment modalities, either alone or in combination, did not have a significant effect on OS (p = 0.210, p = 0.617, p = 0.644, and p = 0.417, respectively). In contrast, osseous site of peripheral localization, limited stage, and metastasis to the bone significantly affected OS (p = 0.015, p < 0.001, and p = 0.042, respectively). Conclusions: ESFTs are aggressive tumors with a high rate of relapse and metastatic potential. Patients with peripheral bone involvement and limited stage had a good prognosis. Appropriate surgical resection, radiotherapy, and aggressive chemotherapy regimens are recommended.